Literature DB >> 32405990

Is faster always better? What is the implication of a shorter time to imaging with tetrofosmin compared to sestamibi?

Kelly Laipply1, Myron Gerson2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32405990     DOI: 10.1007/s12350-020-02143-y

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  5 in total

1.  Efficiency comparison between 99m Tc-tetrofosmin and 99m Tc-sestamibi myocardial perfusion studies.

Authors:  G C Ravizzini; M W Hanson; L K Shaw; T Z Wong; R J Hagge; R A Pagnanelli; D Jain; H S Lima; R E Coleman; S Borges-Neto
Journal:  Nucl Med Commun       Date:  2002-03       Impact factor: 1.690

2.  Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.

Authors:  G Münch; J Neverve; I Matsunari; G Schröter; M Schwaiger
Journal:  J Nucl Med       Date:  1997-03       Impact factor: 10.057

3.  Non-traditional factors affecting referral for coronary angiography following SPECT myocardial perfusion imaging.

Authors:  Shreyas Gowdar; Nasir Hussain; Alan W Ahlberg; Mohammad Elsadany; Guru N Kowlgi; David Silverman; W Lane Duvall
Journal:  J Nucl Cardiol       Date:  2020-11-05       Impact factor: 3.872

4.  Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging.

Authors:  F J Wackers; D S Berman; J Maddahi; D D Watson; G A Beller; H W Strauss; C A Boucher; M Picard; B L Holman; R Fridrich
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

Review 5.  New SPECT and PET radiopharmaceuticals for imaging cardiovascular disease.

Authors:  Oyebola O Sogbein; Matthieu Pelletier-Galarneau; Thomas H Schindler; Lihui Wei; R Glenn Wells; Terrence D Ruddy
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.